Fluoroquinolones Safety in Patients with Staphylococcal Peri
Fluoroquinolones (FQs) are known to be accompanied by significant risks. FQ regimens were found to have a substantially higher rate of unplanned drug discontinuation than non-FQ regimens.

This study included 156 patients over the age of 18 treated for staphylococcal PJI with debridement, antibiotics, and implant retention (DAIR). Of the 156 patients, 64 had total hip arthroplasty (THA) and 92 had total knee arthroplasty (TKA) infections. The primary outcome was rate of unplanned drug discontinuation. Secondary outcomes included incidence of severe ADE, unplanned rifamycin discontinuation, mean time to unplanned regimen discontinuation, and all-cause mortality.

--Overall, unplanned drug discontinuation occurred in 35.6% of patients in the FQ group and 3% of patients in the non-FQ group.

--The rate of unplanned discontinuation of FQ regimens as compared to non-FQ regimens was 27.5% vs 4.2% in THA infections and 42% vs 2.4% in TKA infections.

--There was no significant difference in severe ADEs between FQ and non-FQ regimens in both THA and TKA infections.

--The overall rate of non-severe ADEs in FQ compared to non-FQ regimens was 43.3% vs 6.1%.

--FQs were associated with tendinopathy, myalgia, arthralgia, and nausea.

This gives a realistic picture of the effects of FQ-related adverse events on unplanned discontinuation when used for a long time to treat staphylococcal PJIs.

Source: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab145/6144987?redirectedFrom=fulltext